Selvita names Dr Setareh Shamsili as chief medical officer.
M2 EQUITYBITES-July 25, 2019-Selvita names Dr Setareh Shamsili as chief medical officer
(C)2019 M2 COMMUNICATIONS http://www.m2.com
Drug discovery company Selvita SA (WSE:SLV) reported on Wednesday the addition of Setareh Shamsili, MD, PhD, as its chief medical officer.
Most recently, Dr Shamsili has served as interim chief medical officer at AxImmune, a US-based immuno-oncology company.
Previously, Dr Shamsili was chief medical officer of Merus NV, where she brought the initial two candidates to the clinic for development in acute myeloid leukemia and the treatment of solid tumours.
Earlier in her career, Dr Shamsili served as the global medical leader oncology at Astellas Pharma Global Development.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Jul 25, 2019|
|Previous Article:||RaySearch extends collaboration with Mevion to support advanced HYPERSCAN treatment planning capabilities.|
|Next Article:||Health Catalyst prices IPO at USD26.00 per share.|